Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates Immunotherapy firm AlloVir has extended its research and development alliance with Baylor College of Medicine for the discovery and development of Covid-19 therapies.
The partners aim to create allogeneic, off-the-shelf, virus-specific T-cell therapies using AlloVir’s technology. The new T-cell therapy candidate may target the new SARS-CoV-2, as well as other coronaviruses such as SARS-CoV and MERS-CoV.
The company is working towards a drug that can act as monotherapy, as well as used with its experimental multi-respiratory virus therapy, ALVR106.